Personalized Medicine in cancer care rests on the assumption that genomic profiling can aid in treatment management decisions for patients, yielding both clinical value for patients and economic value for the system. However, genomic profiling technologies are relatively new and the evidence for their clinical and economic utility is limited. Most payers and providers require more evidence to adapt policies and procedures that will lead to widespread access of next generation sequencing (NGS) based diagnostics in clinical practice. This session will feature a discussion on the clinical utility and economic value of NGS-based diagnostic testing in cancer care, including the evidence needed for provider and payer decision-making. Panelists will highlight data sources and original research results that will provide clinical utility and health economic value evidence of genomic profiling technologies.